Vanderbilt-Ingram Cancer Center Archive — Page 24 of 29
-
May 3, 2019
Researchers putting the brakes on lethal childhood cancer
Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers. Although rare — about 20 to 25 new cases are diagnosed annually in the United States — there is no standard effective treatment for the disease, which is driven by loss of an anti-cancer protein called SNF5. The chances are very small that a child will survive a year after MRT diagnosis. -
April 18, 2019
Team explores fungal infection quandary in lung cancer screenings
Serving a region that lies within the tobacco belt, clinicians at Vanderbilt Health face challenges distinguishing lung cancer from histoplasmosis, a fungal infection that creates cancer-mimicking lesions in the lungs. -
April 11, 2019
Study reframes approach to targeted therapy resistance
When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient. -
March 28, 2019
Bladder cancer research fund honors mentor’s lasting influence
The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists. -
March 14, 2019
Cancer Center Ambassadors surpass $1 million in grants
Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants. -
February 28, 2019
Investigators map genomic landscape of very rare cancer
A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer. -
February 28, 2019
VICC launches new telehealth program for CAR-T patients
Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.